Need professional-grade analysis? Visit stockanalysis.com
$3.77B
26.40
640
N/A
ADMA Biologics Inc (ADMA) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $10.78, down 2.09% from the previous close.
Over the past year, ADMA has traded between a low of $8.29 and a high of $24.51. The stock has lost 50.4% over this period. It is currently 56.0% below its 52-week high.
ADMA Biologics Inc has a market capitalization of $3.77B, with a price-to-earnings ratio of 26.40.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Side-by-side comparison against top Healthcare peers.